{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:14:33Z","timestamp":1778210073977,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004470","name":"Daewoong Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-026-04986-7","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:11:12Z","timestamp":1769231472000},"page":"9831-9838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000\u00a0mg in healthy subjects under fasting and fed conditions"],"prefix":"10.1007","volume":"399","author":[{"given":"Surim Meagan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonsuk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-Young","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anhye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yil-Seob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaejin","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seoyeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyounggyoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"4986_CR1","doi-asserted-by":"crossref","unstructured":"ADA Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142025. Diabetes Care 48(Supplement_1):S181-S206","DOI":"10.2337\/dc25-S009"},{"issue":"1","key":"4986_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ et al (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11(1):43","journal-title":"BMC Med"},{"issue":"2","key":"4986_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/cpdd.220","volume":"5","author":"TW de Bruin","year":"2016","unstructured":"de Bruin TW et al (2016) Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clin Pharmacol Drug Dev 5(2):118\u2013130","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4986_CR4","doi-asserted-by":"crossref","unstructured":"El\u2010Damanawi R et al. (2019) Metformin for preventing the progression of chronic kidney disease. Cochrane Database System Rev 2019(9): CD013414","DOI":"10.1002\/14651858.CD013414"},{"issue":"2","key":"4986_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81\u201398","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4986_CR6","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","volume":"60","author":"SJ Griffin","year":"2017","unstructured":"Griffin SJ, Leaver JK, Irving GJ (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60(9):1620\u20131629","journal-title":"Diabetologia"},{"issue":"6","key":"4986_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4093\/dmj.2022.0315","volume":"47","author":"KA Han","year":"2023","unstructured":"Han KA et al (2023) Efficacy and safety of enavogliflozin versus dapagliflozin as add-on to metformin in patients with type 2 diabetes mellitus: a 24-week, double-blind, randomized trial. Diabetes Metab J 47(6):796\u2013807","journal-title":"Diabetes Metab J"},{"issue":"9","key":"4986_CR8","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1111\/bcp.15348","volume":"88","author":"JG Hwang","year":"2022","unstructured":"Hwang JG et al (2022) Dose-dependent glucosuria of DWP16001, a novel selective sodium\u2013glucose cotransporter-2 inhibitor, in healthy subjects. Br J Clin Pharmacol 88(9):4100\u20134110","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4986_CR9","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/bcp.15632","volume":"89","author":"SI Jeong","year":"2023","unstructured":"Jeong SI et al (2023) Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium\u2013glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. Br J Clin Pharmacol 89(6):1780\u20131788","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4986_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/pharmaceutics12090865","volume":"12","author":"J-H Kim","year":"2020","unstructured":"Kim J-H et al (2020) In vitro metabolism of DWP16001, a novel sodium-glucose cotransporter 2 inhibitor, in human and animal hepatocytes. Pharmaceutics 12(9):865","journal-title":"Pharmaceutics"},{"issue":"4","key":"4986_CR11","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bcp.15613","volume":"89","author":"B Kim","year":"2023","unstructured":"Kim B et al (2023a) Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium\u2013glucose cotransporter 2 inhibitor and metformin in healthy subjects. Br J Clin Pharmacol 89(4):1462\u20131470","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4986_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3390\/pharmaceutics15030942","volume":"15","author":"M-S Kim","year":"2023","unstructured":"Kim M-S et al (2023b) Physiologically based pharmacokinetic modelling to predict pharmacokinetics of enavogliflozin, a sodium-dependent glucose transporter 2 inhibitor, in humans. Pharmaceutics 15(3):942","journal-title":"Pharmaceutics"},{"issue":"7","key":"4986_CR13","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/dom.15046","volume":"25","author":"SH Kwak","year":"2023","unstructured":"Kwak SH et al (2023) Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 25(7):1865\u20131873","journal-title":"Diabetes Obes Metab"},{"key":"4986_CR14","unstructured":"Lee S et al (2025) Evaluation of formulation on the pharmacokinetics, safety, and tolerability of enavogliflozin in healthy Korean adults. Naunyn-Schmiedeberg's Arch Pharmacol 1\u20137"},{"issue":"2","key":"4986_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","volume":"28","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Gellad WF (2012) Medication adherence to multi-drug regimens. Clin Geriatr Med 28(2):287","journal-title":"Clin Geriatr Med"},{"issue":"11","key":"4986_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.7326\/M15-2650","volume":"164","author":"NM Maruthur","year":"2016","unstructured":"Maruthur NM et al (2016) Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 164(11):740\u2013751","journal-title":"Ann Intern Med"},{"issue":"3","key":"4986_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/dom.12012","volume":"15","author":"M Nauck","year":"2013","unstructured":"Nauck M et al (2013) Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 15(3):204\u2013212","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4986_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A et al (2024) SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res 120(5):443\u2013460","journal-title":"Cardiovasc Res"},{"issue":"5","key":"4986_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/cpdd.629","volume":"8","author":"V Sahasrabudhe","year":"2019","unstructured":"Sahasrabudhe V et al (2019) Effect of food on the pharmacokinetics of ertugliflozin and its fixed-dose combinations ertugliflozin\/sitagliptin and ertugliflozin\/metformin. Clin Pharmacol Drug Dev 8(5):619\u2013627","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"4986_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/009127009603601105","volume":"36","author":"NC Sambol","year":"1996","unstructured":"Sambol NC et al (1996) Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36(11):1012\u20131021","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4986_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2337\/diacare.29.04.06.dc05-1967","volume":"29","author":"S Schwartz","year":"2006","unstructured":"Schwartz S et al (2006) Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes available to purchase. Diabetes Care 29(4):759\u2013764","journal-title":"Diabetes Care"},{"key":"4986_CR22","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S295459","author":"AK Singh","year":"2021","unstructured":"Singh AK, Singh R, Chakraborty PP (2021) Diabetes monotherapies versus metformin-based combination therapy for the treatment of type 2 diabetes. Int J Gen Med. https:\/\/doi.org\/10.2147\/IJGM.S295459","journal-title":"Int J Gen Med"},{"key":"4986_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/dom.15729","volume":"26","author":"A Solini","year":"2024","unstructured":"Solini A, Tric\u00f2 D (2024) Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence. Diabetes Obes Metab 26:20\u201330","journal-title":"Diabetes Obes Metab"},{"key":"4986_CR24","unstructured":"Tamilselvi M, Srinivas A (2014) Bioequivalence and Pharmacokinetics of Metformin Hydrochloride 1000 mg Tablet extended formulation in healthy Indian male volunteers. J Pharmaceut BioSci 2"},{"issue":"7","key":"4986_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2165\/00003088-200544070-00004","volume":"44","author":"P Timmins","year":"2005","unstructured":"Timmins P et al (2005) Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 44(7):721\u2013729","journal-title":"Clin Pharmacokinet"},{"key":"4986_CR26","doi-asserted-by":"crossref","unstructured":"UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 352(9131):854\u2013865","DOI":"10.1016\/S0140-6736(98)07037-8"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-04986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-04986-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-04986-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:44:51Z","timestamp":1778208291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-04986-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4986"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-04986-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jaejin Na, Jae Min Cho, and Seoyeon Yeon are employees of Daewoong Pharmaceutical. The other authors report no conflicts of interest associated with this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}